CAJ | 학술논문

目的：探讨恩替卡韦联合地塞米松治疗慢加急性肝功能衰竭的疗效。方法将在综合治疗基础上联合恩替卡韦0.5 mg，po，qd和地塞米松10 mg，静滴，qd组设为治疗组（68例）。综合治疗组设为对照组（62例），3周后观察疗效。结果治疗组的生存率为（77.94%，53/68）优于对照组（45.16%，28/62）（P＜0.05）；存活者中，治疗组的HBV-DNA阴转率（92.45%，49/53）明显优于对照组（28.57%，8/28）（P＜0.01）；治疗组的肝功能及PTA的改善优于对照组（P＜0.05）。结论两药联合应用治疗可改善肝功能衰竭患者肝功能及PTA，提高了生存率。
목적：탐토은체잡위연합지새미송치료만가급성간공능쇠갈적료효。방법장재종합치료기출상연합은체잡위0.5 mg，po，qd화지새미송10 mg，정적，qd조설위치료조（68례）。종합치료조설위대조조（62례），3주후관찰료효。결과치료조적생존솔위（77.94%，53/68）우우대조조（45.16%，28/62）（P＜0.05）；존활자중，치료조적HBV-DNA음전솔（92.45%，49/53）명현우우대조조（28.57%，8/28）（P＜0.01）；치료조적간공능급PTA적개선우우대조조（P＜0.05）。결론량약연합응용치료가개선간공능쇠갈환자간공능급PTA，제고료생존솔。
Objective To explore the effect of Entecavir combined with dexamethasone in treatment of patients with acute on chronic liver failure. Method 130 patients with ACLF were randomly divided into control group(n=62) and treatment group(n=68).Patients in treatment group received the ordinary synthetic treatment plus Entecavir and dexamethasone, ones in control group received ordinary synthetic treatment only.The results were observed for 3 weeks ofter beginning of the treatment.Result The survival rate of the treatment group(77.94%, 53/68) was higher than that of the control group (45.16%,28/62)(P<0.05).Among the survivals,the percentage of serum HBV-DNA negative conversion in the treatment group was markedly higher (92.45%, 49/53) than that in the control group(28.57%, 8/28)(P<0.01).In improving the liver function and PTA, the treatment group was better than the control group. Conclusion The combination of Entecavir with dexamethasone can improve the liver function and increase the survival rate of thepatients with ACLF.